Trial Profile
Effacts of alemtuzumab in patients with relapsed refractory multiple sclerosis: Three year Spanish Real-world study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms LemVida
- 27 Apr 2023 Status changed from recruiting to completed, according to Results presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 27 Apr 2023 Results assessing effectiveness of alemtuzumab on quality of life (QoL) of relapsing-remitting multiple sclerosis (RRMS) patients in a real-world setting, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 26 Jul 2017 New trial record